Biogen idec stock market

Founded in by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

Is Biogen Idec Inc. (BIIB) a Good Stock to Buy? - Insider Monkey

It's looking like will turn out to be disappointing for Biogen NASDAQ: Part of the stock's lackluster performance stemmed from a midstage clinical setback for experimental multiple sclerosis drug opicinumab.

The broader slowdown for biotech stocks was another big factor.

However, Biogen appears poised to enjoy a much better Here are three reasons why. Biogen and partner Ionis Pharmaceuticals NASDAQ: IONS expect to launch spinal muscular atropy SMA drug Spinraza by early pending approval. Spinal muscular atrophy is a rare disease, and there is no current treatment available. That means Biogen and Ionis should be able to command a premium price, assuming Spinraza wins approval.

AVXS is also developing a potential SMA treatment, the small biotech is still conducting an early-stage study of the experimental drug while planning a pivotal study.

Spinraza also has another advantage in that it can treat all three types of SMA, while AveXis' candidate will target treatment of only patients with type 1.

Another expected product launch could both help and hurt Biogen. RHHBY hopes to win regulatory approval for multiple sclerosis drug Ocrevus within the next several days. Biogen stands to reap tiered double-digit royalties from any sales of Ocrevus, but the drug will likely also hurt sales of Biogen's Tysabri. The biotech revealed in August that the name of this new company would be Bioverativ.

Bioverativ should have a good shot at success. Biogen shareholders will own a new company with a great growth trajectory. It wouldn't be surprising to see Bioverativ as an acquisition target down the road. The spin-off will also allow Biogen to focus on its core specialty of developing drugs for neurological indications.

Wall Street typically loves spin-offs.

I suspect this one will be a success. There are several possible catalysts next year for the biotech's pipeline.

An early-stage study evaluating BIIB in treating chronic facial pain disorder trigeminal neuralgia wraps up in February Final data collection for the primary outcome of a phase 2 study of experimental Alzheimer's disease drug E is expected in August of next year.

This study is being conducted by Biogen's partner Eisai. Another mid-stage study evaluating Tysabri in treating acute ischemic stroke winds up in July. What about Biogen's late-stage candidates?

Results from a late-stage study of promising Alzheimer's disease treatment aducanumab are still a few years in the future. However, Roche is scheduled to complete data collection for the primary outcome measure for a phase 3 study of Gazyva in treating non-Hodgkin's lymphoma in February. Biogen's prospects in depend on a lot of things falling into place.

The most important of these is approval and successful launch of Spinraza. Barring a major shocker, I don't think that should be a problem. I don't foresee any real risks for Biogen's stock performance with the Bioverativ spin-off. However, it's entirely possible that the market yawns instead of showing excitement.

Regardless, I think the spin-off is a good move for the long run. The biggest risks of all are with Biogen's pipeline candidates. There's going to be plenty of activity next year, with the potential for both wins and losses.

My view is that the biotech will experience more successes than failures with its pipeline, but there's no way to know for sure. All that being said, my prediction is that will be a much better year for Biogen than has been. That sounds about right to me. Biogen's stock seems set to soar in the new year. Keith Speights has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Biogen and Ionis Pharmaceuticals.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

The Motley Fool has a disclosure policy. Keith began writing for the Fool in and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Skip to main content The Motley Fool Fool.

Premium Advice Help Fool Answers Contact Us Login. Latest Stock Picks Stocks Premium Services.

BIIB Stock Price & News - Biogen Inc. - Wall Street Journal

Stock Advisor Flagship service. Rule Breakers High-growth stocks. Income Investor Dividend stocks. Hidden Gems Small-cap stocks. Inside Value Undervalued stocks. Learn How to Invest. Credit Cards Best Credit Cards of Best Credit Card Sign-Up Bonuses Best Balance-Transfer Credit Cards Best Travel Credit Cards Best Cash-Back Credit Cards Best No-Annual-Fee Credit Cards Best Small Business Credit Cards.

Mortgages Compare Mortgage Rates Get Pre-Approved How Much House Can I Afford?

Taxes How to Reduce Your Taxes Deductions Even Pros Overlook Audit-Proof Your Tax Return What Info Should I Keep? Helping the World Invest — Better. How to Invest Learn How to Invest. Personal Finance Credit Cards Best Credit Cards of Best Credit Card Sign-Up Bonuses Best Balance-Transfer Credit Cards Best Travel Credit Cards Best Cash-Back Credit Cards Best No-Annual-Fee Credit Cards Best Small Business Credit Cards. Dec 20, at 3: Prev 1 2 3 4 Next. Motley Fool push notifications are finally here Allow push notifications to help you stay on top of Breaking investing news Earnings coverage Market movers Special offers and more Subscribe to notifications You can unsubscribe at any time.